Subsequent work has focused on constructing CD19 CARs with internal costimulatory domains such as CD28 or 4-1BB, which, when employed in SLE patients, demonstrate similar therapeutic effectiveness and even preventive effects. Here, CD19 is linked to systemic lupus erythematosus.